(Q37810130)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Michel Arock

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

1 reference

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

497-516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083038%20AND%20SRC:MED&resulttype=core&format=json

Familial cutaneous mastocytosis

16 January 2020

cites work

1 reference

A germline mutation in KIT in familial diffuse cutaneous mastocytosis

21 January 2018

1 reference

Clinical and histopathological aspects of cutaneous mastocytosis

21 January 2018

1 reference

Cutaneous mastocytosis -- clinical heterogeneity.

21 January 2018

1 reference

Evidence for altered mast cell proliferation and apoptosis in cutaneous mastocytosis.

21 January 2018

1 reference

Cutaneous mastocytosis: a review focusing on the pediatric population

21 January 2018

1 reference

The liver, spleen, and lymph nodes in mastocytosis

21 January 2018

1 reference

Mast cells and mastocytosis

21 January 2018

1 reference

Bone marrow findings in systemic mastocytosis

21 January 2018

1 reference

Liver findings in generalized mastocytosis. A clinicopathologic study

21 January 2018

1 reference

Diagnostic criteria and classification of mastocytosis: a consensus proposal

21 January 2018

1 reference

Systemic mastocytosis: clinical manifestations and differential diagnosis

21 January 2018

1 reference

Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

21 January 2018

1 reference

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria

21 January 2018

1 reference

Mastocytosis: pathology, genetics, and current options for therapy

21 January 2018

1 reference

Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis.

21 January 2018

1 reference

New developments in mast cell biology

21 January 2018

1 reference

Our perception of the mast cell from Paul Ehrlich to now.

21 January 2018

1 reference

The riddle of the mast cell: kit(CD117)-ligand as the missing link?

21 January 2018

1 reference

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

21 January 2018

1 reference

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

21 January 2018

1 reference

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

21 January 2018

1 reference

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

21 January 2018

1 reference

Current options in the treatment of mast cell mediator-related symptoms in mastocytosis

21 January 2018

1 reference

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

21 January 2018

1 reference

The role of mast cells in osteoporosis

21 January 2018

1 reference

Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders

21 January 2018

1 reference

Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis

21 January 2018

1 reference

Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis.

21 January 2018

1 reference

Mast cells and mast cell neoplasia: a review

21 January 2018

1 reference

Histopathological and immunohistochemical aspects of mastocytosis.

21 January 2018

1 reference

Diagnostic evaluation and classification of mastocytosis

21 January 2018

1 reference

Mastocytosis: current concepts in diagnosis and treatment

21 January 2018

1 reference

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial

21 January 2018

1 reference

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

21 January 2018

1 reference

KIT mutations in mastocytosis and their potential as therapeutic targets

21 January 2018

1 reference

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

21 January 2018

1 reference

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

21 January 2018

1 reference

IgE, mast cells, basophils, and eosinophils

21 January 2018

1 reference

The role of mast cells in host defense and their subversion by bacterial pathogens

21 January 2018

1 reference

Mast cell functions in the innate skin immune system

21 January 2018

1 reference

New roles for mast cells in modulating allergic reactions and immunity against pathogens

21 January 2018

1 reference

A current understanding of Fc epsilon RI-dependent mast cell activation

21 January 2018

1 reference

Development of mast cells from grafted bone marrow cells in irradiated mice

21 January 2018

1 reference

Development, migration, and survival of mast cells

21 January 2018

1 reference

Cytokines involved in growth and differentiation of human basophils and mast cells

21 January 2018

1 reference

Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes

21 January 2018

1 reference

Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor

21 January 2018

1 reference

Development of human mast cells in vitro

21 January 2018

1 reference

Origin of basophils and mast cells

21 January 2018

1 reference

Molecular mechanisms of mast cell development

21 January 2018

1 reference

Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosa

21 January 2018

1 reference

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells

21 January 2018

1 reference

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy

21 January 2018

1 reference

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

21 January 2018

1 reference

Identification of a committed precursor for the mast cell lineage.

21 January 2018

1 reference

Human mast cell proteases and mast cell heterogeneity

21 January 2018

1 reference

Tryptase, a mediator of human mast cells

21 January 2018

1 reference

Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study

21 January 2018

1 reference

Mast-cell-leukocyte cytokine cascades in allergic inflammation

21 January 2018

1 reference

Mast cells in allergy and beyond

21 January 2018

1 reference

Mast cell modulation of the immune response

21 January 2018

1 reference

Mast cells and eosinophils: the two key effector cells in allergic inflammation

21 January 2018

1 reference

Mast cells: new targets for multiple sclerosis therapy?

21 January 2018

1 reference

Mast cells in rheumatoid arthritis

21 January 2018

1 reference

The master switch: the role of mast cells in autoimmunity and tolerance

21 January 2018

1 reference

The controversial role of mast cells in tumor growth

21 January 2018

1 reference

Mast cells are essential intermediaries in regulatory T-cell tolerance

21 January 2018

1 reference

Allergen cleavage by effector cell-derived proteases regulates allergic inflammation.

21 January 2018

1 reference

Mast cells: multifaceted immune cells with diverse roles in health and disease

21 January 2018

1 reference

Classification and diagnosis of mastocytosis: current status

21 January 2018

1 reference

Mastocytosis: state of the art.

21 January 2018

1 reference

Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

21 January 2018

1 reference

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

21 January 2018

1 reference

A proposed classification of mastocytosis incorporating molecular genetics

21 January 2018

1 reference

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria

21 January 2018

1 reference

Mast cell proliferative disorders: current view on variants recognized by the World Health Organization

21 January 2018

1 reference

Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.

21 January 2018

1 reference

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

21 January 2018

1 reference

Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry.

21 January 2018

1 reference

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

21 January 2018

1 reference

21 January 2018

1 reference

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

21 January 2018

1 reference

Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression

21 January 2018

1 reference

Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case?

21 January 2018

1 reference

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

21 January 2018

1 reference

A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val

21 January 2018

1 reference

Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.

21 January 2018

1 reference

The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus

21 January 2018

1 reference

Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation

21 January 2018

1 reference

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

c-Kit--a hematopoietic cell essential receptor tyrosine kinase

21 January 2018

1 reference

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

21 January 2018

1 reference

The role of Kit-ligand in melanocyte development and epidermal homeostasis

21 January 2018

1 reference

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

21 January 2018

1 reference

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal

21 January 2018

1 reference

Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells.

21 January 2018

1 reference

Kit as a human oncogenic tyrosine kinase

21 January 2018

1 reference

Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia

21 January 2018

1 reference

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation

21 January 2018

1 reference

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3

21 January 2018

1 reference

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

21 January 2018

1 reference

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

21 January 2018

1 reference

Establishment of an immature mast cell line from a patient with mast cell leukemia

21 January 2018

1 reference

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

21 January 2018

1 reference

Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene

21 January 2018

1 reference

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

21 January 2018

1 reference

Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis

21 January 2018

1 reference

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature

21 January 2018

1 reference

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

21 January 2018

1 reference

c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation

21 January 2018

1 reference

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

21 January 2018

1 reference

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

21 January 2018

1 reference

Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.

21 January 2018

1 reference

A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors

21 January 2018

1 reference

The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis

21 January 2018

1 reference

Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria

21 January 2018

1 reference

Amplification mechanisms for the enhancement of antigen-mediated mast cell activation

21 January 2018

1 reference

Mastocytosis and allergy.

21 January 2018

1 reference

Mast cells and mastocytosis

21 January 2018

1 reference

Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.

21 January 2018

1 reference

Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy

21 January 2018

1 reference

Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review

21 January 2018

1 reference

Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment

21 January 2018

1 reference

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

21 January 2018

1 reference

Cladribine therapy for systemic mastocytosis.

21 January 2018

1 reference

"Smoldering systemic mastocytosis. "Successful therapy with cladribine

21 January 2018

1 reference

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

21 January 2018

1 reference

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

21 January 2018

1 reference

Dasatinib therapy for systemic mastocytosis: four cases

21 January 2018

1 reference

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.

21 January 2018

1 reference

Targeting CD44 in mast cell regulation

21 January 2018

1 reference

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells.

21 January 2018

1 reference

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

21 January 2018

1 reference

Critical protective role of mast cells in a model of acute septic peritonitis

21 January 2018

1 reference